Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
04 janv. 2022 07h25 HE
|
Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial
01 déc. 2021 07h35 HE
|
Arch Biopartners
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...
Axtria Leads Discussion on Pharma’s Advanced Uses of Data Analytics and Artificial Intelligence With 6 Sessions at PMSA 2021 Annual Conference
16 juin 2021 08h00 HE
|
Axtria Inc.
Berkeley Heights, NJ, June 16, 2021 (GLOBE NEWSWIRE) -- With the elevated importance of data analytics and artificial intelligence (AI)-driven intelligence technology systems for a global life...
Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period - by PMI
11 juin 2021 10h35 HE
|
PMI
Covina, CA, June 11, 2021 (GLOBE NEWSWIRE) -- Rheumatic Fever Treatment Market is estimated with a CAGR of 5.2% during the forecast period. Rheumatic fever is an infectious inflammatory condition...
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation
10 juin 2021 07h20 HE
|
Arch Biopartners
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19
04 mai 2021 07h00 HE
|
Arch Biopartners
TORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Global Thalassemia Treatment Market is estimated to be US$ 14.7 billion by 2030 with a CAGR of 10.40% during the forecast period - By PMI
30 avr. 2021 10h05 HE
|
PMI
Covina, CA, April 30, 2021 (GLOBE NEWSWIRE) -- The Global Thalassemia Treatment Market accounted for US$ 2.3 billion in 2020 and is estimated to be US$ 14.7 billion by 2030 and is anticipated to...
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
07 avr. 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Appointment of Ben Vertannes as Head of Global Marketing
08 mars 2021 02h00 HE
|
Ascension
PRESS RELEASE Appointment of Ben Vertannes as Head of Global Marketing LONDON, March 8, 2021 – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage pharmaceutical company...
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
12 janv. 2021 10h05 HE
|
PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...